Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4).

"Declarations Conflict of interestDSG: Consultant for Dicerna, Inc., a Novo Nordisk Company, Alnylam, Synlogic, Sumitovant, Orfan, BridgeBio/Cantero; Research funding from Dicerna, Inc., a Novo Nordisk Company, Alnylam, Travere; Owner, Moonstone Nutrition; JCL: Consultant for Alnylam, Dicerna Inc., a Novo Nordisk Company, OxThera, BridgeBio/Cantero, Chinook, BioMarin, Synlogic, Novobiome, Oxidien, Federation Bio, Intellia, Precision BioSciences; Research funding from OxThera, Allena, Siemens, Alnylam, Dicerna, Inc, a Novo Nordisk Company, Synlogic, Novobiome, Arkray; JG: Research funding from Dicerna Inc., a Novo Nordisk Company, Alnylam, UniQure; Consultant for Alnylam Eu 2000 CF; Scientific advisor for Alnylam; serves as chair of OxalEurope; GS has nothing to disclose; KR was an employee of Dicerna Inc., a Novo Nordisk Company at the time of the completion of this study; SY is an employee of Dicerna Inc., a Novo Nordisk Company; and BV is an employee of Novo Nordisk. Ethical approvalThis study was conducted in accordance with the provisions of the Declaration of Helsinki, Good Clinical Practice Guidelines of the International Conference on Harmonisation, and all applicable laws and regulations. Informed consentWritten informed consent was obtained from all adult participants and the parents or legal guardians of participating children. All children assented as appropriate. Conflict of interest DSG: Consultant for Dicerna, Inc., a Novo Nordisk Company, Alnylam, Synlogic, Sumitovant, Orfan, BridgeBio/Cantero; Research funding from Dicerna, Inc., a Novo Nordisk Company, Alnylam, Travere; Owner, Moonstone Nutrition; JCL: Consultant for Alnylam, Dicerna Inc., a Novo Nordisk Company, OxThera, BridgeBio/Cantero, Chinook, BioMarin, Synlogic, Novobiome, Oxidien, Federation Bio, Intellia, Precision BioSciences; Research funding from OxThera, Allena, Siemens, Alnylam, Dicerna, Inc, a Novo Nordisk Company, Synlogic, Novobiome, Arkray; JG: Research funding from Dicerna Inc., a Novo Nordisk Company, Alnylam, UniQure; Consultant for Alnylam Eu 2000 CF; Scientific advisor for Alnylam; serves as chair of OxalEurope; GS has nothing to disclose; KR was an employee of Dicerna Inc., a Novo Nordisk Company at the time of the completion of this study; SY is an employee of Dicerna Inc., a Novo Nordisk Company; and BV is an employee of Novo Nordisk."

"Funding The study was supported by Dicerna Pharmaceuticals, Inc., a Novo Nordisk Company (Lexington, MA, USA)"